An integrated manufacturing plant for active pharmaceutical ingredients and formulations, to be located in the Taizhou Medical High-tech Zone, Taizhou city, East China's Jiangsu province, broke ground on Feb 5.
Costing 1 billion yuan ($137.2 million), the facility was invested in by Cavendish (Taizhou) Pharmaceutical and was recently included on the list of 2025 provincial-level major projects.
An artist's rendering of the integrated manufacturing plant for active pharmaceutical ingredients and formulations. [Photo/WeChat account: weigg6666]
The company aims to build a comprehensive preparations workshop, an active pharma ingredients workshop, office buildings and support facilities, including those for storage, power supplies and sewage treatment, as well as to purchase 188 sets of equipment.
On completion, the plant will produce 400 million solid preparations, 20 million solution preparations and 62.5 million injection solutions for the treatment of hypertension, lipid-lowering and other conditions.
The project will generate projected invoiced sales of 1 billion yuan and pay taxes of about 100 million yuan annually.
Nanjing Cavendish Bio-engineering Technology, the parent company of Cavendish (Taizhou) Pharmaceutical, focuses on the research and development of high-tech barrier drugs and innovative drugs.